Industry Research Reports
Global Peptide Therapeutics Market Insights, Forecast to 2031
Industry: Medical Care
Published Date: 2025-05-24
Pages: 158 Pages
Report ld: 4744521
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Peptide Therapeutics Market Size(US$)
CAGR 2025-2031
9.0%
Market Size,2031
USD 74,320
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 44,320 million
Market Forecast in 2031(Value)
US$ 74,320 million
CAGR
9.0%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 74320 million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.0% during the forecast period.
Peptide therapeutics are a class of pharmaceutical drugs composed of short chains of amino acids, typically ranging from 2 to 50 residues, that mimic natural peptides in the body. These drugs are designed to interact with specific cellular targets, such as receptors, enzymes, or ion channels, to regulate physiological functions. Due to their high specificity, low toxicity, and favorable safety profiles, peptide drugs are widely used in the treatment of various diseases, including cancer, diabetes, cardiovascular diseases, and infectious conditions. With advances in peptide engineering, formulation, and delivery technologies, peptide therapeutics have become a growing segment of the biopharmaceutical industry.
The Peptide Therapeutics market is driven by the increasing demand for highly specific and efficient treatments for a wide range of diseases, including cancer, diabetes, cardiovascular conditions, and rare genetic disorders. Peptides, due to their high selectivity, low immunogenicity, and close resemblance to natural biological molecules, are well-suited for targeted therapy with fewer side effects. Technological advancements in peptide synthesis, modification, and drug delivery systems have enhanced their stability and extended their half-life, making them more viable for clinical use. Additionally, the growing investment in biopharmaceutical research and development, along with a favorable regulatory environment for innovative therapies, is accelerating the development and approval of peptide-based drugs.
Despite these advantages, the Peptide Therapeutics market faces several challenges, particularly related to drug delivery and manufacturing. Peptides are generally unstable in the gastrointestinal tract and are rapidly degraded by enzymes, limiting their oral bioavailability and often requiring parenteral administration. This can affect patient compliance and limit market penetration. Moreover, the complex and costly manufacturing processes for peptide drugs, including synthesis, purification, and formulation, pose economic and technical barriers, especially for smaller biotech firms. Overcoming these limitations through innovative formulation strategies and cost-efficient production methods is critical for ensuring broader clinical adoption and long-term market growth.
Global Peptide Therapeutics key players include Sanofi, Novo Nordisk, Takeda, Eli Lilly, Ipsen, etc. Global top five manufacturers hold a share about 65%. North America is the largest market, with a share about 55%, followed by Europe and Asia-Pacific, both have a share about 40 percent. In terms of product, Injection is the largest segment, with a share about 70%. And in terms of application, the largest application is Cancer, followed by Central Nervous System.
In terms of production side, this report researches the Peptide Therapeutics production, growth rate, market share by manufacturers and by region (region level and country level), from 2020 to 2025, and forecast to 2031.
In terms of consumption side, this report focuses on the sales of Peptide Therapeutics by region (region level and country level), by company, by Type and by Application. from 2020 to 2025 and forecast to 2031.
This report presents an overview of global market for Peptide Therapeutics, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2020 - 2025, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Peptide Therapeutics, also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Peptide Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peptide Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptide Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Peptide Therapeutics sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, AbbVie, Ipsen, Ferring, etc.
MARKET SEGMENTATION
By Company
- Sanofi
- Teva
- Novo Nordisk
- Takeda
- Eli Lilly
- AstraZeneca
- Novartis
- AbbVie
- Ipsen
- Ferring
- Merck
- The Medicines
- J & J
- Aurinia Pharmaceuticals
- BioMarin Pharmaceutical
- Apellis Pharmaceuticals
- Lantheus
- CSL Vifor Group
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Injection
- Oral
- Other
Segment by Application
- Cancer
- Metabolic Disorders
- Central Nervous System
- Other
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Peptide Therapeutics production/output of global and key producers (regions/countries). It provides a quantitative analysis of the production, and development potential of each producer in the next six years.
Chapter 3: Sales (consumption), revenue of Peptide Therapeutics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Peptide Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: China by Type, and by Application, sales, and revenue for each segment.
Chapter 10: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 11: Middle East, Africa, Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Therapeutics sales, revenue, price, gross margin, and recent development, etc.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 15: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Injection
1.2.3 Oral
1.2.4 Other
1.3 Market by Application
1.3.1 Global Peptide Therapeutics Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Metabolic Disorders
1.3.4 Central Nervous System
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide Therapeutics Market Perspective (2020-2031)
2.2 Global Peptide Therapeutics Growth Trends by Region
2.2.1 Global Peptide Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peptide Therapeutics Market Size by Region (2020-2031)
2.3 Peptide Therapeutics Market Dynamics
2.3.1 Peptide Therapeutics Industry Trends
2.3.2 Peptide Therapeutics Market Drivers
2.3.3 Peptide Therapeutics Market Challenges
2.3.4 Peptide Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Peptide Therapeutics by Players
3.1.1 Global Peptide Therapeutics Revenue by Players (2020-2025)
3.1.2 Global Peptide Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Peptide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Peptide Therapeutics, Ranking by Revenue, 2023 VS 2024 VS 2025
3.4 Global Market Concentration Ratio
3.4.1 Global Peptide Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Therapeutics Revenue in 2024
3.5 Global Key Players of Peptide Therapeutics Head office and Area Served
3.6 Global Key Players of Peptide Therapeutics, Product and Application
3.7 Global Key Players of Peptide Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type
4.1 Global Peptide Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Peptide Therapeutics Forecasted Market Size by Type (2026-2031)
5 Breakdown Data by Application
5.1 Global Peptide Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Peptide Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peptide Therapeutics Market Size (2020-2031)
6.2 North America Market Size by Type
6.2.1 North America Peptide Therapeutics Market Size by Type (2020-2031)
6.2.2 North America Peptide Therapeutics Market Share by Type (2020-2031)
6.3 North America Market Size by Application
6.3.1 North America Peptide Therapeutics Market Size by Application (2020-2031)
6.3.2 North America Peptide Therapeutics Market Share by Application (2020-2031)
6.4 North America Market Size by Country
6.4.1 North America Peptide Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
6.4.2 North America Peptide Therapeutics Market Size by Country (2020-2031)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Peptide Therapeutics Market Size (2020-2031)
7.2 Europe Market Size by Type
7.2.1 Europe Peptide Therapeutics Market Size by Type (2020-2031)
7.2.2 Europe Peptide Therapeutics Market Share by Type (2020-2031)
7.3 Europe Market Size by Application
7.3.1 Europe Peptide Therapeutics Market Size by Application (2020-2031)
7.3.2 Europe Peptide Therapeutics Market Share by Application (2020-2031)
7.4 Europe Market Size by Country
7.4.1 Europe Peptide Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
7.4.2 Europe Peptide Therapeutics Market Size by Country (2020-2025)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Peptide Therapeutics Market Size (2020-2031)
8.2 China Market Size by Type
8.2.1 China Peptide Therapeutics Market Size by Type (2020-2031)
8.2.2 China Peptide Therapeutics Market Share by Type (2020-2031)
8.3 China Market Size by Application
8.3.1 China Peptide Therapeutics Market Size by Application (2020-2031)
8.3.2 China Peptide Therapeutics Market Share by Application (2020-2031)
9 Asia (excluding China)
9.1 Asia Peptide Therapeutics Market Size (2020-2031)
9.2 Asia Market Size by Type
9.2.1 Asia Peptide Therapeutics Market Size by Type (2020-2031)
9.2.2 Asia Peptide Therapeutics Market Share by Type (2020-2031)
9.3 Asia Market Size by Application
9.3.1 Asia Peptide Therapeutics Market Size by Application (2020-2031)
9.3.2 Asia Peptide Therapeutics Market Share by Application (2020-2031)
9.4 Asia Market Size by Region
9.4.1 Asia Peptide Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
9.4.2 Asia Peptide Therapeutics Market Size by Region (2020-2031)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
9.4.8 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Peptide Therapeutics Market Size (2020-2031)
10.2 Middle East, Africa, and Latin America Market Size by Type
10.2.1 Middle East, Africa, and Latin America Peptide Therapeutics Market Size by Type (2020-2031)
10.2.2 Middle East, Africa, and Latin America Peptide Therapeutics Market Share by Type (2020-2031)
10.3 Middle East, Africa, and Latin America Market Size by Application
10.3.1 Middle East, Africa, and Latin America Peptide Therapeutics Market Size by Application (2020-2031)
10.3.2 Middle East, Africa, and Latin America Market Share by Application (2020-2031)
10.4 Middle East, Africa, and Latin America Market Size by Country
10.4.1 Middle East, Africa, and Latin America Peptide Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
10.4.2 Middle East, Africa, and Latin America Peptide Therapeutics Market Size by Country (2020-2031)
10.4.3 Brazil
10.4.4 Mexico
10.4.5 Turkey
10.4.6 Saudi Arabia
10.4.7 Israel
10.4.8 GCC Countries
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Peptide Therapeutics Introduction
11.1.4 Sanofi Revenue in Peptide Therapeutics Business (2020-2025)
11.1.5 Sanofi Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Peptide Therapeutics Introduction
11.2.4 Teva Revenue in Peptide Therapeutics Business (2020-2025)
11.2.5 Teva Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Peptide Therapeutics Introduction
11.3.4 Novo Nordisk Revenue in Peptide Therapeutics Business (2020-2025)
11.3.5 Novo Nordisk Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Peptide Therapeutics Introduction
11.4.4 Takeda Revenue in Peptide Therapeutics Business (2020-2025)
11.4.5 Takeda Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Details
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Peptide Therapeutics Introduction
11.5.4 Eli Lilly Revenue in Peptide Therapeutics Business (2020-2025)
11.5.5 Eli Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Peptide Therapeutics Introduction
11.6.4 AstraZeneca Revenue in Peptide Therapeutics Business (2020-2025)
11.6.5 AstraZeneca Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Peptide Therapeutics Introduction
11.7.4 Novartis Revenue in Peptide Therapeutics Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Peptide Therapeutics Introduction
11.8.4 AbbVie Revenue in Peptide Therapeutics Business (2020-2025)
11.8.5 AbbVie Recent Development
11.9 Ipsen
11.9.1 Ipsen Company Details
11.9.2 Ipsen Business Overview
11.9.3 Ipsen Peptide Therapeutics Introduction
11.9.4 Ipsen Revenue in Peptide Therapeutics Business (2020-2025)
11.9.5 Ipsen Recent Development
11.10 Ferring
11.10.1 Ferring Company Details
11.10.2 Ferring Business Overview
11.10.3 Ferring Peptide Therapeutics Introduction
11.10.4 Ferring Revenue in Peptide Therapeutics Business (2020-2025)
11.10.5 Ferring Recent Development
11.11 Merck
11.11.1 Merck Company Details
11.11.2 Merck Business Overview
11.11.3 Merck Peptide Therapeutics Introduction
11.11.4 Merck Revenue in Peptide Therapeutics Business (2020-2025)
11.11.5 Merck Recent Development
11.12 The Medicines
11.12.1 The Medicines Company Details
11.12.2 The Medicines Business Overview
11.12.3 The Medicines Peptide Therapeutics Introduction
11.12.4 The Medicines Revenue in Peptide Therapeutics Business (2020-2025)
11.12.5 The Medicines Recent Development
11.13 J & J
11.13.1 J & J Company Details
11.13.2 J & J Business Overview
11.13.3 J & J Peptide Therapeutics Introduction
11.13.4 J & J Revenue in Peptide Therapeutics Business (2020-2025)
11.13.5 J & J Recent Development
11.14 Aurinia Pharmaceuticals
11.14.1 Aurinia Pharmaceuticals Company Details
11.14.2 Aurinia Pharmaceuticals Business Overview
11.14.3 Aurinia Pharmaceuticals Peptide Therapeutics Introduction
11.14.4 Aurinia Pharmaceuticals Revenue in Peptide Therapeutics Business (2020-2025)
11.14.5 Aurinia Pharmaceuticals Recent Development
11.15 BioMarin Pharmaceutical
11.15.1 BioMarin Pharmaceutical Company Details
11.15.2 BioMarin Pharmaceutical Business Overview
11.15.3 BioMarin Pharmaceutical Peptide Therapeutics Introduction
11.15.4 BioMarin Pharmaceutical Revenue in Peptide Therapeutics Business (2020-2025)
11.15.5 BioMarin Pharmaceutical Recent Development
11.16 Apellis Pharmaceuticals
11.16.1 Apellis Pharmaceuticals Company Details
11.16.2 Apellis Pharmaceuticals Business Overview
11.16.3 Apellis Pharmaceuticals Peptide Therapeutics Introduction
11.16.4 Apellis Pharmaceuticals Revenue in Peptide Therapeutics Business (2020-2025)
11.16.5 Apellis Pharmaceuticals Recent Development
11.17 Lantheus
11.17.1 Lantheus Company Details
11.17.2 Lantheus Business Overview
11.17.3 Lantheus Peptide Therapeutics Introduction
11.17.4 Lantheus Revenue in Peptide Therapeutics Business (2020-2025)
11.17.5 Lantheus Recent Development
11.18 CSL Vifor Group
11.18.1 CSL Vifor Group Company Details
11.18.2 CSL Vifor Group Business Overview
11.18.3 CSL Vifor Group Peptide Therapeutics Introduction
11.18.4 CSL Vifor Group Revenue in Peptide Therapeutics Business (2020-2025)
11.18.5 CSL Vifor Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Peptide Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Injection
Table 3. Key Players of Oral
Table 4. Key Players of Other
Table 5. Global Peptide Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Peptide Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Market Size by Region (2020-2031) & (US$ Million)
Table 8. Global Peptide Therapeutics Market Share by Region (2020-2031)
Table 9. Market Trends
Table 10. Market Drivers
Table 11. Market Challenges
Table 12. Market Restraints
Table 13. Global Peptide Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 14. Global Peptide Therapeutics Market Share by Players (2020-2025)
Table 15. Global Top Peptide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Therapeutics as of 2024)
Table 16. Global Peptide Therapeutics Industry Ranking 2023 VS 2024
Table 17. Global 5 Largest Players Market Share by Peptide Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 18. Global Key Players of Peptide Therapeutics, Headquarters and Area Served
Table 19. Global Key Players of Peptide Therapeutics, Product and Application
Table 20. Global Key Players of Peptide Therapeutics, Date of Enter into This Industry
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Market Size by Type (2020-2025) & (US$ Million)
Table 23. Global Peptide Therapeutics Revenue Market Share by Type (2020-2025)
Table 24. Global Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 25. Global Peptide Therapeutics Revenue Market Share by Type (2026-2031)
Table 26. Global Market Size by Application (2020-2025) & (US$ Million)
Table 27. Global Peptide Therapeutics Revenue Market Share by Application (2020-2025)
Table 28. Global Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 29. Global Peptide Therapeutics Revenue Market Share by Application (2026-2031)
Table 30. North America Market Size by Type (2020-2031) & (US$ Million)
Table 31. North America Market Size by Application (2020-2031) & (US$ Million)
Table 32. North America Peptide Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Market Size by Country (2020-2031) & (US$ Million)
Table 34. Europe Market Size by Type (2020-2031) & (US$ Million)
Table 35. Europe Market Size by Application (2020-2031) & (US$ Million)
Table 36. Europe Peptide Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Market Size by Country (2020-2025) & (US$ Million)
Table 38. China Market Size by Type (2020-2031) & (US$ Million)
Table 39. China Market Size by Application (2020-2031) & (US$ Million)
Table 40. Asia Market Size by Type (2020-2031) & (US$ Million)
Table 41. Asia Market Size by Application (2020-2025) & (US$ Million)
Table 42. Asia Peptide Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia Market Size by Region (2020-2031) & (US$ Million)
Table 44. Middle East, Africa, and Latin America Market Size by Type (2020-2031) & (US$ Million)
Table 45. Middle East, Africa, and Latin America Market Size by Application (2020-2031) & (US$ Million)
Table 46. Middle East, Africa, and Latin America Peptide Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East, Africa, and Latin America Market Size by Country (2020-2031) & (US$ Million)
Table 48. Sanofi Company Details
Table 49. Sanofi Business Overview
Table 50. Sanofi Peptide Therapeutics Product
Table 51. Sanofi Revenue (2020-2025) & (US$ Million)
Table 52. Sanofi Recent Development
Table 53. Teva Company Details
Table 54. Teva Business Overview
Table 55. Teva Peptide Therapeutics Product
Table 56. Teva Revenue (2020-2025) & (US$ Million)
Table 57. Teva Recent Development
Table 58. Novo Nordisk Company Details
Table 59. Novo Nordisk Business Overview
Table 60. Novo Nordisk Peptide Therapeutics Product
Table 61. Novo Nordisk Revenue (2020-2025) & (US$ Million)
Table 62. Novo Nordisk Recent Development
Table 63. Takeda Company Details
Table 64. Takeda Business Overview
Table 65. Takeda Peptide Therapeutics Product
Table 66. Takeda Revenue (2020-2025) & (US$ Million)
Table 67. Takeda Recent Development
Table 68. Eli Lilly Company Details
Table 69. Eli Lilly Business Overview
Table 70. Eli Lilly Peptide Therapeutics Product
Table 71. Eli Lilly Revenue (2020-2025) & (US$ Million)
Table 72. Eli Lilly Recent Development
Table 73. AstraZeneca Company Details
Table 74. AstraZeneca Business Overview
Table 75. AstraZeneca Peptide Therapeutics Product
Table 76. AstraZeneca Revenue (2020-2025) & (US$ Million)
Table 77. AstraZeneca Recent Development
Table 78. Novartis Company Details
Table 79. Novartis Business Overview
Table 80. Novartis Peptide Therapeutics Product
Table 81. Novartis Revenue (2020-2025) & (US$ Million)
Table 82. Novartis Recent Development
Table 83. AbbVie Company Details
Table 84. AbbVie Business Overview
Table 85. AbbVie Peptide Therapeutics Product
Table 86. AbbVie Revenue (2020-2025) & (US$ Million)
Table 87. AbbVie Recent Development
Table 88. Ipsen Company Details
Table 89. Ipsen Business Overview
Table 90. Ipsen Peptide Therapeutics Product
Table 91. Ipsen Revenue (2020-2025) & (US$ Million)
Table 92. Ipsen Recent Development
Table 93. Ferring Company Details
Table 94. Ferring Business Overview
Table 95. Ferring Peptide Therapeutics Product
Table 96. Ferring Revenue (2020-2025) & (US$ Million)
Table 97. Ferring Recent Development
Table 98. Merck Company Details
Table 99. Merck Business Overview
Table 100. Merck Peptide Therapeutics Product
Table 101. Merck Revenue (2020-2025) & (US$ Million)
Table 102. Merck Recent Development
Table 103. The Medicines Company Details
Table 104. The Medicines Business Overview
Table 105. The Medicines Peptide Therapeutics Product
Table 106. The Medicines Revenue (2020-2025) & (US$ Million)
Table 107. The Medicines Recent Development
Table 108. J & J Company Details
Table 109. J & J Business Overview
Table 110. J & J Peptide Therapeutics Product
Table 111. J & J Revenue (2020-2025) & (US$ Million)
Table 112. J & J Recent Development
Table 113. Aurinia Pharmaceuticals Company Details
Table 114. Aurinia Pharmaceuticals Business Overview
Table 115. Aurinia Pharmaceuticals Peptide Therapeutics Product
Table 116. Aurinia Pharmaceuticals Revenue (2020-2025) & (US$ Million)
Table 117. Aurinia Pharmaceuticals Recent Development
Table 118. BioMarin Pharmaceutical Company Details
Table 119. BioMarin Pharmaceutical Business Overview
Table 120. BioMarin Pharmaceutical Peptide Therapeutics Product
Table 121. BioMarin Pharmaceutical Revenue (2020-2025) & (US$ Million)
Table 122. BioMarin Pharmaceutical Recent Development
Table 123. Apellis Pharmaceuticals Company Details
Table 124. Apellis Pharmaceuticals Business Overview
Table 125. Apellis Pharmaceuticals Peptide Therapeutics Product
Table 126. Apellis Pharmaceuticals Revenue (2020-2025) & (US$ Million)
Table 127. Apellis Pharmaceuticals Recent Development
Table 128. Lantheus Company Details
Table 129. Lantheus Business Overview
Table 130. Lantheus Peptide Therapeutics Product
Table 131. Lantheus Revenue (2020-2025) & (US$ Million)
Table 132. Lantheus Recent Development
Table 133. CSL Vifor Group Company Details
Table 134. CSL Vifor Group Business Overview
Table 135. CSL Vifor Group Peptide Therapeutics Product
Table 136. CSL Vifor Group Revenue (2020-2025) & (US$ Million)
Table 137. CSL Vifor Group Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide Therapeutics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 2. Global Peptide Therapeutics Market Share by Type: 2024 VS 2031
Figure 3. Injection Features
Figure 4. Oral Features
Figure 5. Other Features
Figure 6. Global Peptide Therapeutics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Global Peptide Therapeutics Market Share by Application: 2024 VS 2031
Figure 8. Cancer Case Studies
Figure 9. Metabolic Disorders Case Studies
Figure 10. Central Nervous System Case Studies
Figure 11. Other Case Studies
Figure 12. Peptide Therapeutics Report Years Considered
Figure 13. Global Peptide Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Peptide Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Peptide Therapeutics Market Share by Region: 2024 VS 2031
Figure 16. Global Peptide Therapeutics Market Share by Players in 2024
Figure 17. Global Top Peptide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Therapeutics as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Peptide Therapeutics Revenue in 2024
Figure 19. North America Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Peptide Therapeutics Market Share by Type (2020-2031)
Figure 21. North America Peptide Therapeutics Market Share by Application (2020-2031)
Figure 22. North America Peptide Therapeutics Market Share by Country (2020-2031)
Figure 23. United States Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Peptide Therapeutics Market Share by Type (2020-2031)
Figure 27. Europe Peptide Therapeutics Market Share by Application (2020-2031)
Figure 28. Europe Peptide Therapeutics Market Share by Country (2020-2031)
Figure 29. Germany Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. China Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. China Peptide Therapeutics Market Share by Type (2020-2031)
Figure 37. China Peptide Therapeutics Market Share by Application (2020-2031)
Figure 38. Asia Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Asia Peptide Therapeutics Market Share by Type (2020-2031)
Figure 40. Asia Peptide Therapeutics Market Share by Application (2020-2031)
Figure 41. Asia Peptide Therapeutics Market Share by Region (2020-2031)
Figure 42. Japan Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. South Korea Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. China Taiwan Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. India Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Australia Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Peptide Therapeutics Market Share by Type (2020-2031)
Figure 50. Middle East, Africa, and Latin America Peptide Therapeutics Market Share by Application (2020-2031)
Figure 51. Middle East, Africa, and Latin America Peptide Therapeutics Market Share by Country (2020-2031)
Figure 52. Brazil Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Mexico Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Turkey Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. Israel Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. GCC Countries Peptide Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 58. Sanofi Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 59. Teva Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 60. Novo Nordisk Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 61. Takeda Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 62. Eli Lilly Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 63. AstraZeneca Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 64. Novartis Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 65. AbbVie Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 66. Ipsen Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 67. Ferring Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 68. Merck Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 69. The Medicines Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 70. J & J Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 71. Aurinia Pharmaceuticals Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 72. BioMarin Pharmaceutical Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 73. Apellis Pharmaceuticals Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 74. Lantheus Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 75. CSL Vifor Group Revenue Growth Rate in Peptide Therapeutics Business (2020-2025)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 9.0% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
What is the annual compound growth rate of the global Peptide Therapeutics market size from 2025 to 2031?
What was the global market size of Peptide Therapeutics in 2025?
What was the global market size of Peptide Therapeutics in 2031?
Which companies rank high in the global Peptide Therapeutics market?
Related Reports
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 80340 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-02-14
Pages: 152
USD 4900.00
(Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Peptide Therapeutics market size was US$ 44320 million in 2025 and is forecast to reach a readjusted size of US$ 80340 million by 2032 with a CAGR of 9.0% during the forecast period 2026-2032.
Published Date: 2026-02-14
Pages: 108
USD 4250.00
(Single User License)
Global Peptide Therapeutics Market Research Report 2026
The global Peptide Therapeutics market was valued at US$ 44320 million in 2025 and is anticipated to reach US$ 80340 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Published Date: 2026-02-14
Pages: 131
USD 2900.00
(Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Peptide Therapeutics was estimated to be worth US$ 44320 million in 2025 and is projected to reach US$ 80340 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published Date: 2026-02-14
Pages: 122
USD 3950.00
(Single User License)
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 41000 million in 2024 to US$ 74320 million by 2031, at a CAGR of 9.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-09-11
Pages: 151
USD 4900.00
(Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-05-24
Pages: 139
USD 3950.00
(Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Peptide Therapeutics market size was US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-05-24
Pages: 110
USD 4250.00
(Single User License)
Global Peptide Therapeutics Market Research Report 2025
The global market for Peptide Therapeutics was valued at US$ 41000 million in the year 2024 and is projected to reach a revised size of US$ 74320 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published Date: 2025-05-24
Pages: 94
USD 2900.00
(Single User License)
Global Peptide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Peptide Therapeutics was estimated to be worth US$ 41000 million and is forecast to reach approximately US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 143
USD 5900.00
(Single User License)
Peptide Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 120
USD 3950.00
(Single User License)
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 80340 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-02-14
Pages: 152
USD 4900.00 (Single User License)Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Peptide Therapeutics market size was US$ 44320 million in 2025 and is forecast to reach a readjusted size of US$ 80340 million by 2032 with a CAGR of 9.0% during the forecast period 2026-2032.
Published: 2026-02-14
Pages: 108
USD 4250.00 (Single User License)Global Peptide Therapeutics Market Research Report 2026
The global Peptide Therapeutics market was valued at US$ 44320 million in 2025 and is anticipated to reach US$ 80340 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Published: 2026-02-14
Pages: 131
USD 2900.00 (Single User License)Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Peptide Therapeutics was estimated to be worth US$ 44320 million in 2025 and is projected to reach US$ 80340 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published: 2026-02-14
Pages: 122
USD 3950.00 (Single User License)Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 41000 million in 2024 to US$ 74320 million by 2031, at a CAGR of 9.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-09-11
Pages: 151
USD 4900.00 (Single User License)Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-05-24
Pages: 139
USD 3950.00 (Single User License)Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Peptide Therapeutics market size was US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-05-24
Pages: 110
USD 4250.00 (Single User License)Global Peptide Therapeutics Market Research Report 2025
The global market for Peptide Therapeutics was valued at US$ 41000 million in the year 2024 and is projected to reach a revised size of US$ 74320 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published: 2025-05-24
Pages: 94
USD 2900.00 (Single User License)Global Peptide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Peptide Therapeutics was estimated to be worth US$ 41000 million and is forecast to reach approximately US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 143
USD 5900.00 (Single User License)Peptide Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 120
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now